Literature DB >> 15554925

Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells.

Shikhar Mehrotra1, Arvind Chhabra, Abolokita Chakraborty, Subhasis Chattopadhyay, Mark Slowik, Robert Stevens, Ryan Zengou, Clinton Mathias, Lisa H Butterfield, David I Dorsky, James S Economou, Bijay Mukherji, Nitya G Chakraborty.   

Abstract

Dendritic cells (DC) play critical roles in generating an immune response and in inducing tolerance. Diverse microenvironmental factors can 'polarize' DC toward an immunogenic or non-immunogenic phenotype. Among the various microenvironmental factors, interleukin-10 (IL-10) exhibits a potent immunosuppressive effect on antigen-presenting cells (APC). Here, we show that monocyte-derived DC generated in the presence of IL-10 exhibit a profound down-regulation of many genes that are associated with immune activation and show that the IL-10-grown DC are poor stimulators of CD8(+) T cells in a strictly autologous and major histocompatibility complex (MHC) class I-restricted melanoma antigen recognized by T cells (MART-1) epitope presentation system. However, these IL-10-grown DC can efficiently activate the epitope-specific CD8(+) T cells when they are made to present the epitope following transduction with an adenoviral vector expressing the MART-1 antigen. In addition, we show that the MART-1 protein colocalizes with the MHC class I protein, equally well, in the iDC and in the DC cultured in presence of IL-10 when both DC types are infected with the viral vector. We also show that the vector transduced DC present the MART-1(27-35) epitope for a sustained period compared to the peptide pulsed DC. These data suggest that although DCs generated in the presence of IL-10 tend to be non-immunogenic, they are capable of processing and presenting an antigen when the antigen is synthesized within the DC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15554925      PMCID: PMC1782594          DOI: 10.1111/j.1365-2567.2004.01978.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  54 in total

Review 1.  From synapses to immunological memory: the role of sustained T cell stimulation.

Authors:  A Lanzavecchia; F Sallusto
Journal:  Curr Opin Immunol       Date:  2000-02       Impact factor: 7.486

2.  Natural adjuvants: endogenous activators of dendritic cells.

Authors:  S Gallucci; M Lolkema; P Matzinger
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

3.  Maturation of human monocyte-derived dendritic cells studied by microarray hybridization.

Authors:  A B Dietz; P A Bulur; G J Knutson; R Matasić; S Vuk-Pavlović
Journal:  Biochem Biophys Res Commun       Date:  2000-09-07       Impact factor: 3.575

Review 4.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

5.  Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma.

Authors:  R Philip; S E Alters; E Brunette; J Ashton; J Gadea; J Yau; J Lebkowski; M Philip
Journal:  J Immunother       Date:  2000-01       Impact factor: 4.456

6.  Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells.

Authors:  A Ribas; L H Butterfield; B Hu; V B Dissette; A Y Chen; A Koh; S N Amarnani; J A Glaspy; W H McBride; J S Economou
Journal:  J Immunother       Date:  2000-01       Impact factor: 4.456

7.  Regulatory activity of autocrine IL-10 on dendritic cell functions.

Authors:  S Corinti; C Albanesi; A la Sala; S Pastore; G Girolomoni
Journal:  J Immunol       Date:  2001-04-01       Impact factor: 5.422

8.  Identification of genes specifically expressed in human activated and mature dendritic cells through serial analysis of gene expression.

Authors:  S I Hashimoto; T Suzuki; S Nagai; T Yamashita; N Toyoda; K Matsushima
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

9.  Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma.

Authors:  N G Chakraborty; J R Sporn; A F Tortora; S H Kurtzman; H Yamase; M T Ergin; B Mukherji
Journal:  Cancer Immunol Immunother       Date:  1998-09       Impact factor: 6.968

10.  The induction of tolerance by dendritic cells that have captured apoptotic cells.

Authors:  R M Steinman; S Turley; I Mellman; K Inaba
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

View more
  8 in total

1.  Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35.

Authors:  Arvind Chhabra; Nitya G Chakraborty; Bijay Mukherji
Journal:  Clin Immunol       Date:  2008-01-14       Impact factor: 3.969

2.  Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.

Authors:  A Escobar; M López; A Serrano; M Ramirez; C Pérez; A Aguirre; R González; J Alfaro; M Larrondo; M Fodor; C Ferrada; F Salazar-Onfray
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 3.  New approaches to the development of adenoviral dendritic cell vaccines in melanoma.

Authors:  Lisa H Butterfield; Lazar Vujanovic
Journal:  Curr Opin Investig Drugs       Date:  2010-12

4.  AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.

Authors:  Viktoria N Evdokimova; Yang Liu; Douglas M Potter; Lisa H Butterfield
Journal:  J Immunother       Date:  2007 May-Jun       Impact factor: 4.456

5.  Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

Authors:  Lisa H Butterfield; Begonya Comin-Anduix; Lazar Vujanovic; Yohan Lee; Vivian B Dissette; Jin-Quan Yang; Hong T Vu; Elizabeth Seja; Denise K Oseguera; Douglas M Potter; John A Glaspy; James S Economou; Antoni Ribas
Journal:  J Immunother       Date:  2008-04       Impact factor: 4.456

6.  Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.

Authors:  Leeann T Blalock; Jennifer Landsberg; Michelle Messmer; Jian Shi; Angela D Pardee; Ronald Haskell; Lazar Vujanovic; John M Kirkwood; Lisa H Butterfield
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

7.  Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.

Authors:  Lisa H Butterfield; Lazar Vujanovic; Patricia M Santos; Deena M Maurer; Andrea Gambotto; Joel Lohr; Chunlei Li; Jacob Waldman; Uma Chandran; Yan Lin; Huang Lin; Hussein A Tawbi; Ahmad A Tarhini; John M Kirkwood
Journal:  J Immunother Cancer       Date:  2019-04-24       Impact factor: 13.751

8.  Discovery of novel interacting partners of PSMD9, a proteasomal chaperone: Role of an Atypical and versatile PDZ-domain motif interaction and identification of putative functional modules.

Authors:  Nikhil Sangith; Kannan Srinivasaraghavan; Indrajit Sahu; Ankita Desai; Spandana Medipally; Arun Kumar Somavarappu; Chandra Verma; Prasanna Venkatraman
Journal:  FEBS Open Bio       Date:  2014-06-06       Impact factor: 2.693

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.